Lynparza

Lynparza boosts long-term survival in early breast cancer
Pharmaphorum
Thu, 12/12/24 - 11:29 am
AstraZeneca
breast cancer
Merck
Lynparza
Merck Reveals Mixed Data From Keytruda/Lynparza Regime In Ovarian Cancer
Yahoo/Benzinga
Mon, 12/9/24 - 11:06 am
Merck
Keytruda
Lynparza
ovarian cancer
clinical trials
AstraZeneca’s Imfinzi-Lynparza Combo Wins Landmark EU Nod for Endometrial Cancer
BioSpace
Wed, 08/14/24 - 10:58 am
AstraZeneca
Europe
Imfinzi
Lynparza
endometrial cancer
AstraZeneca’s Lynparza to remain dominant in PARP inhibitors market with $4 billion in sales by 2027
Biopharma Reporter
Thu, 04/25/24 - 11:36 am
AstraZeneca
PARP inhibitors
Merck
Lynparza
ovarian cancer
Merck combination treatment for lung cancer fails late-stage study
Reuters
Thu, 03/21/24 - 11:13 am
Merck
Keytruda
Lynparza
AstraZeneca
non small cell lung cancer
AstraZeneca Shows Lynparza Combo Could Address Unmet Endometrial Cancer Need
BioSpace
Mon, 03/18/24 - 05:19 pm
AstraZeneca
Lynparza
Imfinzi
endometrial cancer
For Merck, Lynparza fails to improve on Keytruda in first-line lung cancer
Fierce Pharma
Thu, 12/7/23 - 12:00 pm
Merck
Keytruda
non-small cell lung cancer
Lynparza
AstraZeneca
Merck KGaA pays $169M for selective PARP1 drug, stepping up challenge to AstraZeneca and Gilead
Fierce Biotech
Mon, 10/30/23 - 11:58 am
Merck KGaA
PARP inhibitors
Lynparza
Zejula
AstraZeneca
Gilead Sciences
solid tumors
ESMO: AstraZeneca proposes adding Lynparza to Imfinzi as endometrial cancer race heats up
Fierce Pharma
Mon, 10/23/23 - 09:07 am
ESMO
AstraZeneca
Merck
Lynparza
endometrial cancer
AstraZeneca, Merck's Lynparza picks up new NICE recommendation
Fierce Pharma
Fri, 06/9/23 - 10:15 am
AstraZeneca
Merck
Lynparza
NICE
UK
ovarian cancer
fallopian tube cancer
ASCO: AstraZeneca guns for wider ovarian cancer market with Imfinzi-Lynparza combo. Will the FDA buy the plan?
Fierce Pharma
Sun, 06/4/23 - 04:24 pm
ASCO 2023
AstraZeneca
Lynparza
Imfinzi
ovarian cancer
FDA clears narrow use of Lynparza in prostate cancer, continuing ‘shift’ on PARP drugs
BioPharma Dive
Thu, 06/1/23 - 11:53 am
AstraZeneca
Merck
Lynparza
prostate cancer
FDA
AstraZeneca reports positive results from endometrial cancer therapy trial
Clinical Trials Arena
Mon, 05/29/23 - 12:24 pm
AstraZeneca
endometrial cancer
clinical trials
Imfinzi
Lynparza
AstraZeneca's drug combo shows positive results in late-stage cancer trial
Reuters
Fri, 05/26/23 - 10:09 am
ASCO 2023
AstraZeneca
Imfinzi
Lynparza
endometrial cancer
With negative FDA panel vote, AstraZeneca's Lynparza looks set for narrow nod in prostate cancer
Fierce Pharma
Mon, 05/1/23 - 10:16 am
AstraZeneca
Merck
Lynparza
metastatic castration-resistant prostate cancer
FDA Questions Efficacy of Merck-AstraZeneca’s Lynparza Ahead of Adcomm
BioSpace
Thu, 04/27/23 - 10:58 pm
Merck
AstraZeneca
FDA
Lynparza
metastatic castration-resistant prostate cancer
Trailing AstraZeneca and Merck, Junshi reports phase 3 ovarian cancer success for Lynparza rival
Fierce Biotech
Wed, 04/12/23 - 11:39 am
Junshi Biosciences
PARP inhibitors
ovarian cancer
Merck
AstraZeneca
Lynparza
AstraZeneca's Lynparza-Imfinzi combo clears PhIII trial in ovarian cancer
Endpoints
Wed, 04/5/23 - 10:14 am
AstraZeneca
Lynparza
Imfinzi
ovarian cancer
clinical trials
FDA asks advisers to review Lynparza amid growing scrutiny of PARP drugs
BioPharma Dive
Sun, 03/5/23 - 03:08 pm
Merck
AstraZeneca
Lynparza
FDA
PARP inhibitors
AstraZeneca, Merck's Lynparza to face FDA panel in prostate cancer bid as PARP scrutiny escalates
Fierce Pharma
Thu, 03/2/23 - 11:02 pm
AstraZeneca
Merck
Lynparza
FDA
prostate cancer

Pages